Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 132 - 136 Metin Dili: İngilizce DOI: 10.14744/SEMB.2022.36048 İndeks Tarihi: 21-06-2022

Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer

Öz:
Objectives: In the present study, we investigated the effects of Vitamin D (vit D) deficiency on aggressiveness of papillary thyroid cancer (PTC). Methods: Patients with PTC confirmed with pathological examination, whom were operated by a single surgeon between 2012 and 2017, were included in the study. The data of the patients were analyzed retrospectively. Cancers other than PTC, patients with hyperthyroidism and/or using antithyroid drugs were excluded from the study. The patients were classified as four quartiles according to serum Vit D levels; category 1 (<7.1 ng/mL), category 2 (7.2–11.8 ng/mL), category 3 (11.9–23.4 ng/mL) and category 4 (>23.5 ng/mL). Results: A total of 133 patients (103 female, 30 male) with mean age of 46.4±13.6 (17–82) years were included in the study. There was no significant difference between the categories in terms of preoperative Vit D values according to the evaluated tumor ag- gressiveness characteristics. It was determined that the presence of tumor with a size above 1 cm and T3/4 tumor were not affected by Vit D level. There was no significant difference between Vit D categories regarding the characteristics of aggressiveness such as multicentricity, lymphovascular invasion, central, and lateral metastases. Conclusion: According to our results, serum Vit D levels are not associated with the aggressive tumor characteristics of PTC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:491S−9S.
  • 2. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342−57.
  • 3. Mondul AM, Weinstein SJ, Layne TM, Albanes D. Vitamin D and cancer risk and mortality: state of the science, gaps, and chal- lenges. Epidemiol Rev 2017;39:28−48.
  • 4. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016;388:2783−95.
  • 5. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017;18:153−65.
  • 6. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011;86:50−60.
  • 7. Binkley N, Dawson-Hughes B, Durazo-Arvizu R, Thamm M, Tian L, Merkel JM, et al. Vitamin D measurement standardization: The way out of the chaos. J Steroid Biochem Mol Biol 2017;173:117−21.
  • 8. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911−30.
  • 9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Niki- forov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differen- tiated thyroid cancer: The American Thyroid Association Guide- lines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1−133.
  • 10. Göktaş O, Ersoy C, Ercan I, Can FE. Vitamin D status in the adult population of Bursa-Turkey. Eur J Gen Pract 2020;26:156−62.
  • 11. Öncül Börekçi N. Current information on vitamin D deficiency. Jour Turk Fam Phy 2019;10:35−42.
  • 12. Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thy- roid cancer. Thyroid 2013;23:1079−86.
  • 13. Ahn HY, Chung YJ, Park KY, Cho BY. Serum 25-hydroxyvitamin D level does not affect the aggressiveness and prognosis of papil- lary thyroid cancer. Thyroid 2016;26:429−33.
  • 14. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: the impacts of cir- culating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:2327−36.
  • 15. Zhao J, Wang H, Zhang Z, Zhou X, Yao J, Zhang R, et al. Vitamin D deficiency as a risk factor for thyroid cancer: A meta-analysis of case-control studies. Nutrition 2019;57:5−11.
  • 16. Kim JR, Kim BH, Kim SM, Oh MY, Kim WJ, Jeon YK, et al. Low serum 25 hydroxyvitamin D is associated with poor clinicopathologic characteristics in female patients with papillary thyroid cancer. Thyroid 2014;24:1618−24.
  • 17. Thanasitthichai S, Prasitthipayong A, Boonmark K, Purisa W, Guayraksa K. Negative impact of 25-hydroxyvitamin D deficiency on breast cancer survival. Asian Pac J Cancer Prev 2019;20:3101−6.
  • 18. Ferrer-Mayorga G, Larriba MJ, Crespo P, Muñoz A. Mechanisms of action of vitamin D in colon cancer. J Steroid Biochem Mol Biol 2019;185:1−6.
APA DEMİRCİOGLU Z, AYGUN N, DEMİRCİOGLU M, OZGUVEN B, ULUDAG M (2022). Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. , 132 - 136. 10.14744/SEMB.2022.36048
Chicago DEMİRCİOGLU Zeynep Gul,AYGUN Nurcihan,DEMİRCİOGLU Mahmut Kaan,OZGUVEN Banu Yilmaz,ULUDAG Mehmet Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. (2022): 132 - 136. 10.14744/SEMB.2022.36048
MLA DEMİRCİOGLU Zeynep Gul,AYGUN Nurcihan,DEMİRCİOGLU Mahmut Kaan,OZGUVEN Banu Yilmaz,ULUDAG Mehmet Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. , 2022, ss.132 - 136. 10.14744/SEMB.2022.36048
AMA DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. . 2022; 132 - 136. 10.14744/SEMB.2022.36048
Vancouver DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. . 2022; 132 - 136. 10.14744/SEMB.2022.36048
IEEE DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M "Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer." , ss.132 - 136, 2022. 10.14744/SEMB.2022.36048
ISNAD DEMİRCİOGLU, Zeynep Gul vd. "Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer". (2022), 132-136. https://doi.org/10.14744/SEMB.2022.36048
APA DEMİRCİOGLU Z, AYGUN N, DEMİRCİOGLU M, OZGUVEN B, ULUDAG M (2022). Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni, 56(1), 132 - 136. 10.14744/SEMB.2022.36048
Chicago DEMİRCİOGLU Zeynep Gul,AYGUN Nurcihan,DEMİRCİOGLU Mahmut Kaan,OZGUVEN Banu Yilmaz,ULUDAG Mehmet Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni 56, no.1 (2022): 132 - 136. 10.14744/SEMB.2022.36048
MLA DEMİRCİOGLU Zeynep Gul,AYGUN Nurcihan,DEMİRCİOGLU Mahmut Kaan,OZGUVEN Banu Yilmaz,ULUDAG Mehmet Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni, vol.56, no.1, 2022, ss.132 - 136. 10.14744/SEMB.2022.36048
AMA DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni. 2022; 56(1): 132 - 136. 10.14744/SEMB.2022.36048
Vancouver DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni. 2022; 56(1): 132 - 136. 10.14744/SEMB.2022.36048
IEEE DEMİRCİOGLU Z,AYGUN N,DEMİRCİOGLU M,OZGUVEN B,ULUDAG M "Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer." Şişli Etfal Hastanesi Tıp Bülteni, 56, ss.132 - 136, 2022. 10.14744/SEMB.2022.36048
ISNAD DEMİRCİOGLU, Zeynep Gul vd. "Low Vitamin D Status is Not Associated with the Aggressive Pathological Features of Papillary Thyroid Cancer". Şişli Etfal Hastanesi Tıp Bülteni 56/1 (2022), 132-136. https://doi.org/10.14744/SEMB.2022.36048